Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Inhibition of ERK signaling for treatment of ERRα positive TNBC

PLoS ONE(2023)10.1371/journal.pone.0283047Source: DataRank Database

Inhibition of ERK signaling for treatment of ERRα positive TNBC is a research paper published in PLoS ONE (2023). On theSindex it has a DataRank of 0. It has been cited 4 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access4 citations

Download PDF

Cite:

Linked data & code

uniprot

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 0.37)OA: goldTopics (52)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Esther Miller,N Birnbaum ORCID,Elisheva Miller,Shoshana Erblich,Alyssa G. Schuck

Live enrichment

PubMed:37163498 PMC:PMC10171695 OpenAlex:https://openalex.org/W4376133464

NIH

Grant: CA220021

NCI NIH HHS

Grant: R15 CA220021

National Institutes of Health

Grant: 1R15CA220021-01

Targeting Estrogen Related Receptor alpha in triple negative breast cancer

Fundação para a Ciência e a Tecnologia, I.P.

Grant: PTDC/CCI-INF/6762/2020

MS3: New foundations for micro-services and serverless systems

Applebaum Foundation

FWCI

0.37

Citation Percentile

0.5%

Citation Trend

2024

2025

2026

goldLicense: cc-by

journalhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0283047&type=printable

publisherhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0283047&type=printable

publisherhttps://dx.plos.org/10.1371/journal.pone.0283047

journalhttp://dx.doi.org/10.1371/journal.pone.0283047

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37163498

Fields of Study

Melanoma and MAPK PathwaysHER2/EGFR in Cancer ResearchEstrogen and related hormone effects03 medical and health sciences0302 clinical medicineHumansFemaleTriple Negative Breast NeoplasmsDrug Inverse AgonismReceptors, EstrogenTamoxifenCell Line, TumorCell ProliferationERRalpha Estrogen-Related Receptor

MeSH Terms

ERRalpha Estrogen-Related ReceptorFemaleHumansReceptors, EstrogenTamoxifenCell Line, TumorCell ProliferationDrug Inverse AgonismTriple Negative Breast Neoplasms

Keywords

Triple-negative breast cancerTamoxifenBreast cancerMAPK/ERK pathwayCancer researchContext (archaeology)Estrogen receptorMedicineCancerDownregulation and upregulationInternal medicineKinaseAgonistOncologyBiologyReceptorCell biologyERRalpha Estrogen-Related ReceptorDrug Inverse AgonismScienceQRTriple Negative Breast NeoplasmsReceptors, EstrogenCell Line, TumorHumansFemaleResearch ArticleCell Proliferation

Sustainable Development Goals

SDG 0: Good health and well-being

Inhibition of ERK signaling for treatment of ERRα positive TNBC

FAIR Checklist

Authors (7)

Funding (5 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)